Vir Biotechnology: Up On Prostate Data And Astellas Deal - I'm (Long-Term) Bullish

Edmund InghamInvesting Group LeaderFollow5ShareSavePlay(17min)CommentsSummaryVir Biotechnology, Inc. surges on positive Phase 1 data for VIR-5500 and a major global partnership with Astellas in prostate cancer.VIR-5500 demonstrated a favorable safety profile and 45% ORR at higher doses, with Astellas providing $335M upfront and up to $1.37B in milestones.Recent licensing deals and a strong cash position ($781.6M) help offset 2025 net loss of $(438M), while pipeline advances target HDV and multiple oncology indications.I initiate VIR stock with a Buy rating, citing de-risked prospects from Astellas, robust long-term pipeline potential, and patience for future catalysts.Looking for option income ideas that focus on capital preservation? I offer this and much more at my exclusive investing ideas service, Haggerston BioHealth. Learn More » chanakon laorob/iStock via Getty Images Investment Overview Vir Biotechnology, Inc. (VIR) stock is soaring today, up nearly 30% in early trading, reaching >$9.5 per share, which reflects a market cap valuation of $1.33bn. San Francisco, California-headquartered Vir, which describes itself as:This article was written byEdmund Ingham14.74K FollowersFollowEdmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston BioHealth. The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, integrated financial statements, discounted cash flow analysis and market by market analysis. Learn more.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.